These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 31863486)

  • 1. MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression.
    Lozano E; Asensio M; Perez-Silva L; Banales JM; Briz O; Marin JJG
    Hepatology; 2020 Sep; 72(3):949-964. PubMed ID: 31863486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma.
    Merino-Azpitarte M; Lozano E; Perugorria MJ; Esparza-Baquer A; Erice O; Santos-Laso Á; O'Rourke CJ; Andersen JB; Jiménez-Agüero R; Lacasta A; D'Amato M; Briz Ó; Jalan-Sakrikar N; Huebert RC; Thelen KM; Gradilone SA; Aransay AM; Lavín JL; Fernández-Barrena MG; Matheu A; Marzioni M; Gores GJ; Bujanda L; Marin JJG; Banales JM
    J Hepatol; 2017 Jul; 67(1):72-83. PubMed ID: 28237397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide.
    Ortiz-Rivero S; Peleteiro-Vigil A; Abete L; Lozano E; Hammer HS; Giacomo SD; Abad M; Boix L; Forner A; Reig M; Macias RIR; Pötz O; Marin JJG; Briz O
    Biomed Pharmacother; 2024 Jan; 170():116038. PubMed ID: 38141281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
    Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
    Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.
    Lozano E; Macias RIR; Monte MJ; Asensio M; Del Carmen S; Sanchez-Vicente L; Alonso-Peña M; Al-Abdulla R; Munoz-Garrido P; Satriano L; O'Rourke CJ; Banales JM; Avila MA; Martinez-Chantar ML; Andersen JB; Briz O; Marin JJG
    Hepatology; 2019 Oct; 70(4):1246-1261. PubMed ID: 30972782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MBD2 regulates the progression and chemoresistance of cholangiocarcinoma through interaction with WDR5.
    Wang D; Chen J; Wu G; Xiong F; Liu W; Wang Q; Kuai Y; Huang W; Qi Y; Wang B; He R; Chen Y
    J Exp Clin Cancer Res; 2024 Sep; 43(1):272. PubMed ID: 39350229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A live single-cell reporter system reveals drug-induced plasticity of a cancer stem cell-like population in cholangiocarcinoma.
    Kongtanawanich K; Prasopporn S; Jamnongsong S; Thongsin N; Payungwong T; Okada S; Hokland M; Wattanapanitch M; Jirawatnotai S
    Sci Rep; 2024 Sep; 14(1):22619. PubMed ID: 39349745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOX2 knockdown slows cholangiocarcinoma progression through inhibition of transcriptional activation of lncRNA PVT1.
    Yu A; Zhao L; Kang Q; Li J; Chen K; Fu H
    Biochem J; 2020 Sep; 477(18):3527-3540. PubMed ID: 32812642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity, toxicity, and anticancer activity of Zingiber officinale Roscoe against cholangiocarcinoma.
    Plengsuriyakarn T; Viyanant V; Eursitthichai V; Tesana S; Chaijaroenkul W; Itharat A; Na-Bangchang K
    Asian Pac J Cancer Prev; 2012; 13(9):4597-606. PubMed ID: 23167387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.
    Lampis A; Carotenuto P; Vlachogiannis G; Cascione L; Hedayat S; Burke R; Clarke P; Bosma E; Simbolo M; Scarpa A; Yu S; Cole R; Smyth E; Mateos JF; Begum R; Hezelova B; Eltahir Z; Wotherspoon A; Fotiadis N; Bali MA; Nepal C; Khan K; Stubbs M; Hahne JC; Gasparini P; Guzzardo V; Croce CM; Eccles S; Fassan M; Cunningham D; Andersen JB; Workman P; Valeri N; Braconi C
    Gastroenterology; 2018 Mar; 154(4):1066-1079.e5. PubMed ID: 29113809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells.
    Seubwai W; Vaeteewoottacharn K; Kraiklang R; Umezawa K; Okada S; Wongkham S
    Oncol Res; 2016 Jan; 23(1-2):21-8. PubMed ID: 26802647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Tumor and Chemosensitizing Effects of the CDK Inhibitor Dinaciclib on Cholangiocarcinoma
    Sungwan P; Kidoikhammouan S; Thonsri U; Saengboonmee C; Wongkham S; Okada S; Seubwai W
    In Vivo; 2024; 38(5):2284-2293. PubMed ID: 39187317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance.
    Yuan X; Li J; Coulouarn C; Lin T; Sulpice L; Bergeat D; De La Torre C; Liebe R; Gretz N; Ebert MPA; Dooley S; Weng HL
    Br J Cancer; 2018 Nov; 119(11):1358-1366. PubMed ID: 30420613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.
    Tepsiri N; Chaturat L; Sripa B; Namwat W; Wongkham S; Bhudhisawasdi V; Tassaneeyakul W
    World J Gastroenterol; 2005 May; 11(18):2748-53. PubMed ID: 15884115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs.
    Sanchon-Sanchez P; Briz O; Macias RIR; Abad M; Sanchez-Martin A; Marin JJG; Lozano E
    Biomed Pharmacother; 2023 Dec; 168():115658. PubMed ID: 37832404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor.
    Permpoon U; Khan F; Vadevoo SMP; Gurung S; Gunassekaran GR; Kim MJ; Kim SH; Thuwajit P; Lee B
    Mol Pharm; 2020 Nov; 17(11):4077-4088. PubMed ID: 32881535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis.
    Du YC; Oshima H; Oguma K; Kitamura T; Itadani H; Fujimura T; Piao YS; Yoshimoto T; Minamoto T; Kotani H; Taketo MM; Oshima M
    Gastroenterology; 2009 Oct; 137(4):1346-57. PubMed ID: 19549530
    [TBL] [Abstract][Full Text] [Related]  

  • 18.  Thymosin β10 as a predictive biomarker of response to 5-fluorouracil chemotherapy in cholangiocarcinoma.
    Sribenja S; Natthasirikul N; Vaeteewoottacharn K; Sawanyawisuth K; Wongkham C; Jearanaikoon P; Wongkham S
    Ann Hepatol; 2016; 15(4):577-85. PubMed ID: 27236157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways.
    Chen Q; Li W; Wan Y; Xia X; Wu Q; Chen Y; Lai Z; Yu C; Li W
    Hepatology; 2012 Jun; 55(6):1820-9. PubMed ID: 22213475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitizing cholangiocarcinoma to chemotherapy by inhibition of the drug-export pump MRP3.
    Asensio M; Briz O; Herraez E; Perez-Silva L; Espinosa-Escudero R; Bueno-Sacristan D; Peleteiro-Vigil A; Hammer H; Pötz O; Kadioglu O; Banales JM; Martinez-Chantar ML; Avila MA; Macias RIR; Efferth T; Marin JJG; Lozano E
    Biomed Pharmacother; 2024 Nov; 180():117533. PubMed ID: 39405909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.